PRT 3789
Alternative Names: PRT-3789Latest Information Update: 19 Sep 2024
At a glance
- Originator Prelude Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action SMARCA2 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Sep 2024 Adverse event, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours released by Prelude Therapeutics
- 09 Sep 2024 Adverse event and pharmacodynamics data from a phase I trial in Solid tumours released by Prelude Therapeutics
- 20 Aug 2024 Prelude Therapeutics plans to initiate phase II clinical combination trial in the fourth quarter of 2024 (Combination therapy)